Moneycontrol
HomeNewsBusinessMedical devices, digital to drive growth for LTTS in coming quarters: CEO Keshab Panda

Medical devices, digital to drive growth for LTTS in coming quarters: CEO Keshab Panda

When the pandemic struck, while IT services providers were able to weather the storm better, the same could not be said for engineering service providers such as LTTS. For instance, for the June 2020 quarter, LTTS’ revenues declined 11.8 percent y-o-y. The September quarter, too, saw revenue dropping 9.9 percent.

December 11, 2020 / 17:36 IST
Story continues below Advertisement

After bagging its largest-deal ever on Dec 10, L&T Technology Services (LTTS) is confident about growth next year, driven by clients’ technology spending and the growing focus on medtech, CEO Keshab Panda said.

When the engineering services firm won a five-year $100 million plant engineering deal in the oil and gas sector yesterday, it sent its stock price soaring to a 52-week high of Rs 1,883.45.

Story continues below Advertisement

“We have signed large deals to the tune of $40 million and $50 million. But this is the biggest deal in any engineering services firms,” Panda told Moneycontrol.

Recently IT majors like Infosys and Wipro have also signed large engineering service deals with automotive firms like Rolls-Royce and Marelli.
“I am hoping Q3 and Q4 we will do more. So FY22 looks very good,” Panda added.

When the pandemic struck, while IT services providers were able to weather the storm better, the same could not be said for engineering service providers such as LTTS. For instance, for the June 2020 quarter, LTTS’ revenues declined 11.8 percent y-o-y. The September quarter, too, saw revenue dropping 9.9 percent.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show